Long-Term Effectiveness of the Live Zoster Vaccine in Preventing Shingles: A Cohort Study

American Journal of Epidemiology

Volumn 187, Issue 1, 2018, Pages 161-169

  Baxter, Roger ^a   Bartlett, Joan ^a   Fireman, Bruce ^a   Marks, Morgan ^b   Hansen, John ^a   Lewis, Edwin ^a   Aukes, Laurie ^a   Chen, Yong ^b   Klein, Nicola P ^a   Saddier, Patricia ^b  

^a DIVISION OF RESEARCH   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

herpes zoster; herpes zoster vaccine; vaccine effectiveness

Indexed keywords

CORTICOSTEROID; LIVE VACCINE; VARICELLA ZOSTER VACCINE;

COHORT ANALYSIS; CONFIDENCE INTERVAL; GENETIC MARKER; IMMUNE RESPONSE; LONG-TERM CHANGE; VACCINATION; VACCINE;

ADULT; AGED; ARTICLE; CALIFORNIA; CHILDBIRTH; CLINICAL TRIAL; COHORT ANALYSIS; COMORBIDITY; DEMOGRAPHY; DRUG EFFICACY; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; IMMUNIZATION; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED PATIENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POPULATION RESEARCH; PROSPECTIVE STUDY; VACCINATION; VERY ELDERLY; DRUG EFFECT; LEGISLATION AND JURISPRUDENCE; PROPORTIONAL HAZARDS MODEL; REGRESSION ANALYSIS; STATISTICS AND NUMERICAL DATA; TIME; TREATMENT OUTCOME; VARICELLA ZOSTER VIRUS;

CALIFORNIA; UNITED STATES;

AGED; AGED, 80 AND OVER; CALIFORNIA; FEMALE; FOLLOW-UP STUDIES; HERPES ZOSTER; HERPES ZOSTER VACCINE; HERPESVIRUS 3, HUMAN; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; TIME; TREATMENT OUTCOME; VACCINATION;

EID: 85040628610     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwx245     Document Type: Article

References (23)

1. Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007; 82(11):1341-1349.
2. Lin YH, Huang LM, Chang IS, et al. Disease burden and epidemiology of herpes zoster in pre-vaccine Taiwan. Vaccine. 2010;28(5):1217-1220.
3. Cohen JI. Clinical practice: herpes zoster. N Engl J Med. 2013; 369(3):255-263.
4. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6):e004833.
5. Harpaz R, Ortega-Sanchez IR, Seward JF, et al. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008; 57(RR-5):1-30; quiz CE2-4.
6. Centers for Disease Control and Prevention (CDC). Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years. MMWR Morb Mortal Wkly Rep. 2011;60(44):1528.
7. Hales CM, Harpaz R, Ortega-Sanchez I, et al. Update on recommendations for use of herpes zoster vaccine. MMWR Morb Mortal Wkly Rep. 2014;63(33):729-731.
8. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271-2284.
9. Schmader KE, Oxman MN, Levin MJ, et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis. 2012; 55(10):1320-1328.
10. Gordon NP. Similarity of the Adult Kaiser Permanente Membership in Northern California to the Insured and General Population in Northern California: Statistics From the 2011 California Health Interview Survey. 2015. https://divisionofresearch.kaiserpermanente.org/projects/memberhealthsurvey/SiteCollectionDocuments/chis-non-kp- 2011.pdf. Published June 19, 2015. Accessed October 6, 2017.
11. Selby JV, Uratsu CS, Fireman B, et al. Kaiser permanente medical care program. In: Strom B, ed. Pharmacoepidemiology. 4th ed. West Sussex, England: John Wiley & Sons Ltd; 2005:241-260.
12. Healthcare Cost and Utilization Project (HCUP). Clinical Classifications Software (CCS) for ICD-9-CM. Rockville, MD: Agency for Healthcare Research and Quality; March 2017. www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp. Accessed October 6, 2017.
13. Omachi TA, Gregorich SE, Eisner MD, et al. Risk adjustment for health care financing in chronic disease: what are we missing by failing to account for disease severity? Med Care. 2013;51(8):740-747.
14. Morrison VA, Johnson GR, Schmader KE, et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis. 2015; 60(6):900-909.
15. Schmader KE, Levin MJ, Gnann JW Jr, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis. 2012;54(7):922-928.
16. Tseng HF, Smith N, Harpaz R, et al. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA. 2011;305(2):160-166.
17. Tseng HF, Harpaz R, Luo Y, et al. Declining effectiveness of herpes zoster vaccine in adults aged ≥60 years. J Infect Dis. 2016;213(12):1872-1875.
18. Langan SM, Smeeth L, Margolis DJ, et al. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Med. 2013;10(4):e1001420.
19. Izurieta HS, Wernecke M, Kelman J, et al. Effectiveness and duration of protection provided by the live-attenuated herpes zoster vaccine in the medicare population ages 65 years and older. Clin Infect Dis. 2017; 64(6):785-793.
20. Tseng HF, Tartof S, Harpaz R, et al. Vaccination against zoster remains effective in older adults who later undergo chemotherapy. Clin Infect Dis. 2014;59(7):913-919.
21. Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012;308(1):43-49.
22. Hernán MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183(8):758-764.
23. Fireman B, Lee J, Lewis N, et al. Influenza vaccination and mortality: differentiating vaccine effects from bias. Am J Epidemiol. 2009;170(5):650-656.